Global Locations

Erlotinib D6



Chemical Properties of 'Erlotinib D6'

CAT No. :

CS-O-03064
CAS Registry No. : 1034651-23-4
Category : Isotope Labelled Compounds
Molecular Weight: 399.47
Molecular Formula : C₂₂H₁₇D₆N₃O₄



OTHER INFORMATION of 'Erlotinib D6'
Purity : Not less than 95 %
Therapeutic : Anti-Cancer / Oncology
Isotopic Enrichment : Not less than 98 %
Purity : Not less than 95 %
Therapeutic : Anti-Cancer / Oncology
Isotopic Enrichment : Not less than 98 %
Applicationnotes :"Labelled Erlotinib. Selective epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor. Antineoplastic.;Labeled Erlotinib, intended for use as an internal standard for the quantification of Erlotinib by GC- or LC-mass spectrometry."
Synonym :Not available
References :"Moyer; J,D,; et al,: Cancer Res,; 57; 4838 (1997); Hidalgo; M,; et al,: J, Clin, Oncol,; 19; 3267 (2001); Perez-Soler; R,; et al,: J, Clin, Oncol,; 22; 3238 (2004); Blackhall; F,H,; et al,: Expert Opin, Pharmacother,; 6; 995 (2005);"
Smileys :C#CC1=CC=CC(NC2=NC=NC3=C2C=C(C(OCCOC([2H])([2H])[2H])=C3)OCCOC([2H])([2H])[2H])=C1
Appearance :White to off white solid
Custom Duty : Applicable
Port of Loading : Canada
Expected Dispatch : 15-Aug-2022
Taxes : Not Applicable
Refund Policy : 30-days money back
Custom Duty : Applicable
Port of Loading : Canada
Expected Dispatch : 15-Aug-2022
Taxes : Not Applicable
Refund Policy : 30-days money back


More information about Erlotinib


Erlotinib, sold under the brand name Tarceva among others, is a medication used to treat non-small cell lung cancer (NSCLC) and pancreatic cancer. Specifically it is used for NSCLC with mutations in the epidermal growth factor receptor (EGFR) \u2014 either an exon 19 deletion (del19) or exon 21 (L858R) substitution mutation \u2014 which has spread to other parts of the body. It is taken by mouth.

Common side effects include rash, diarrhea, muscle pain, joint pain, and cough. Serious side effects may include lung problems, kidney problems, liver failure, gastrointestinal perforation, stroke, and corneal ulceration. Use in pregnancy may harm the baby. It is a receptor tyrosine kinase inhibitor, which acts on the epidermal growth factor receptor (EGFR).

Erlotinib was approved for medical use in the United States in 2004. It is on the World Health Organization's List of Essential Medicines.





This page contains information about Erlotinib D6 , Erlotinib D6 cas, Erlotinib D6 synthesis, Erlotinib D6 suppliers

What is Erlotinib D6 ?
Erlotinib D6 falls under Isotope Labelled Compounds of Erlotinib."Labelled Erlotinib. Selective epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor. Antineoplastic.;Labeled Erlotinib, intended for use as an internal standard for the quantification of Erlotinib by GC- or LC-mass spectrometry."
What is the CAS Number of Erlotinib D6?
The CAS Number of Erlotinib D6 is 1034651-23-4
Who are the suppliers of Erlotinib D6?
CLEARSYNTH is a worldwide supplier of Erlotinib D6

Related compounds of Erlotinib D6

Looking for a discounted price or need more info for 'Erlotinib D6 (CS-O-03064)' ?

If you are looking for Bulk purchase, Discounted Price, etc. please share your email and the exact quantity you are looking for, our team will respond to you within 30 mins with all the required information.

Looking for a discounted price or need more info for 'Erlotinib D6 (CS-O-03064)' ?

If you are looking for Bulk purchase, Discounted Price, etc. please share your email and the exact quantity you are looking for, our team will respond to you within 30 mins with all the required information.